Observational studyAnesthesiology2026
Effect of Weight-based versus Absolute Norepinephrine Dosing on Mortality Risk in Obese Patients with Septic Shock: An Observational, Multicohort, Retrospective Study.
Observational study in Anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The usual suspects: a pragmatic framework to identify and address reversible contributors in apparent refractory septic shock.Critical care (London, England) · 2026Review
- Absolute, weight-based, fixed-dose, or phenotype-guided? Rethinking the meaning of vasopressor dose in critical care.Annals of intensive care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNorepinephrine dose is used as an indicator of severity and a decision-making tool in septic shock management, influencing the initiation of adjuvant therapies, life support limitation, and mortality estimation. However, weight-based dosing may affect its accuracy, particularly given the rising global incidence of obesity. The objective was to assess how body mass index (BMI) influences the relationship between norepinephrine dosing strategy (absolute vs . weight-based) and observed mortality in patients with septic shock.
methodsRetrospective analysis of six open-access data sets encompassing more than 300 intensive care units (ICUs) in four countries. The relationship with ICU mortality of both absolute and weight-based norepinephrine dosing was analyzed in the same set of septic shock patients using nonparametric generalized additive models, adjusted by disease severity.
resultsAmong 386,792 critically ill patients screened, 10,246 septic shock patients were identified. Patients had a Sequential Organ Failure Assessment score of 7 [25th and 75th percentiles, 5 and 10], required a norepinephrine dose of 0.1 [25th and 75th percentiles, 0.05 and 0.2] μg · kg -1 · min -1 (7 [25th and 75th percentiles, 3.4 and 15.8] μg/min), and presented lactate levels of 3.0 [25th and 75th percentiles, 2.3 and 4.8] mmol/l at diagnosis. A total of 2,858 (28%) patients had a BMI above 30 kg/m 2 . Sequential Organ Failure Assessment-adjusted estimated mortality using weight-based norepinephrine dosing was significantly affected by BMI, with a mean difference in predicted mortality of 14.5% (95% CI, 13.7 to 15.3%; PAnalysis of Deviance < 0.001) between obese and nonobese patients. At higher norepinephrine doses (greater than 0.3 μg · kg -1 · min -1 ), weight-based dosing led to a progressive mortality underestimation with increasing BMI, reaching mortality divergences of up to 26% at doses of 1 μg · kg -1 · min -1 between patients with BMIs of 20 and 50 kg/m 2 . In contrast, mortality estimation by absolute norepinephrine dosing was not affected by BMI (mean difference in predicted mortality between obese and nonobese 0.3% (95% CI, -0.1 to 0.6%; PAnalysis of Deviance = 0.715).
conclusionsWeight-based norepinephrine dosing may underestimate ICU mortality in obese patients with septic shock, especially at higher doses, distorting risk stratification and potentially influencing clinical decision-making. Absolute dosing offers a simpler, consistent approach across BMI categories and dose ranges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.